Cure Arthritis Naturally

Cure Arthritis Naturally

Get Instant Access

1. Shimp LA. Safety issues in the pharmacologic management of chronic pain in the elderly. Pharmacotherapy 1998;18:1313-1322.

2. Latham J, Davis BD. The socioeconomic impact of chronic pain. Disabil Rehabil 1994;16:39-44.

3. Crook J, Rodeout E, Browne G. The prevalence of pain complaints in a general population. Pain 1984;18:299-314.

4. Workman BS, Ciccone V, Christophidis N. Pain management for the elderly. Aust Fam Physician 1989;18:1515-1527.

5. Ferrell BA. Pain management in elderly people. J Am Geriatr Soc 1991;39:64-73.

6. Pitkala K, Standberg T, Tilvis R. Management of nonmalignant pain in home-dwelling older people: a population-based survey. J Am Geriatr Soc 2002;50:1861-1865.

7. Landi F, Onder G, Cesari M, et al. Pain management in frail, community-living elderly patients. Arch Intern Med 2001;161:2721-2724.

8. Cavalieri T. Pain management in the elderly. J Am Osteopath Assoc 2002;102:481-485.

9. Beyth R, Shorr R. Epidemiology of adverse drug reactions in the elderly by drug class. Drugs Aging 1999;14:231-239.

10. Popp B, Portenoy R. Management of chronic pain in the elderly: pharmacology of opioids and other analgesic drugs. In: Ferrell BR, Ferrell BA, eds.

Pain in the Elderly, Task Force on Pain in the Elderly. Seattle, WA: IASP Press; 1996:21-34.

11. Pasero C, Rred B, McCaffery M. Pain in the elderly. In: McCaffery M, Pasero C, eds. Pain Clinical Manual. 2nd ed. St. Louis, MO: Mosby; 1999:674-710.

12. Kaiko RF, Wallenseoin SL, Rogers AG, et al. Narcotics in the elderly. Med Clin North Am 1982;66:1079-1089.

13. Kaiko RF. Age and morphine analgesia in cancer patients with postoperative pain. Clin Pharmacol Ther 1980;28:823-826.

14. Bellville JW, Forrest WH Jr, Miller E, et al. Influence of age on pain relief from analgesics. A study of postoperative patients. JAMA 1971;217:1835-1841.

15. Parmelee PA, Latz IR, Lawton MP. The relation of pain to depression among institutionalized aged. J Gerontol 1991;46:P15-P21.

16. Beers MH. Age-related changes as a risk factor for medication-related problems. Generations [serial on-line] Winter 2000-2001;24. Available at: Accessed June 17, 2002.

17. Gloth FM. Pain management in older adults: prevention and treatment. J Am Geriatr Soc 2001;49:188-199.

18. Furst DE, Munster T. Nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, nonopioid analgesics, and drugs used in gout. In: Katzung BG, ed. Basic and Clinical Pharmacology. 8th ed. New York, NY: McGraw-Hill; 2001:615.

19. Chandrasckharan NV, Dai H, Turepu Roos KL, et al. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci U S A 2002;99(21):13,926-13,931.

20. Henry C. COX-3 found: new variant of cyclooxygenase may explain acetaminophen mechanism. Chemical and Engineering News [serial on-line] 2002;80:16. Available at: 8038notw3.html. Accessed February 8, 2003.

21. McEvoy GK, ed. AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2002:2099.

22. American Medical Directors Association. Chronic Pain Management in the Long-Term Care Setting. Columbia, MD: American Medical Directors Association; 1999.

23. AGS Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc 2002;50:1-20.

24. Amadio P Jr, Cummings DM. Evaluation of acetaminophen in the management of osteoarthritis of the knee. Curr Ther Res 1983;34:59-66.

25. Bradley JD, Brandt KD, Katz BP, et al. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patient with osteoarthritis of the knee. N Engl J Med 1991;325:87-91.

Williams HJ, Ward JR, Egger MJ, et al. Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis Rheum 1993;9:1196-1206.

Eccles M, Freemantle N, Mason J, for the North of England Non-steroidal Anti-Inflammatory Drug Guideline Development Group. North of England Evidence Based Guideline Development Project: summary guideline for non-steroidal anti-inflammatory drugs versus basic analgesia in treating the pain of degenerative arthritis. BMJ 1998;317:526-530. Altman RD, AP Study Group. Ibuprofen, acetaminophen and placebo in osteoarthritis of the knee: a 6-day double-blind study [abstract]. Arthritis Rheum 1999;42(Suppl 9):S403.

Pincus T, Callahan LF, Wolfe F, et al. Arthrotec compared to acetaminophen: a clinical trial in patients with osteoarthritis of the hip or knee [abstract]. Arthritis Rheum 1999;42(Suppl 9):S404. Geba GP, Weaver AL, Polis AB, et al. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee. JAMA 2002;287:64-71. Saseen JJ. Which is most effective for osteoarthritis of the knee: rofecoxib, celecoxib, or acetaminophen? J Fam Pract 2002;51:307. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoar-thritis of the hip and knee. Arthritis Rheum 2002;43:1905-1915. American Pain Society. Guideline for the Management of Pain in Osteoar-thritis, Rheumatoid Arthritis, and Juvenile Chronic Arthritis. 2nd ed. Glenview, Il: American Pain Society; 2002.

Clissold SP. Paracetamol and phenacetin. Drugs 1986;32(Suppl 4):46-59. Shamoon M, Hochberg MC. The role of acetaminophen in the management of patients with osteoarthritis. Am J Med 2001;110(3A):46S-49S. Bannwarth B, Fehourcq F, Lagrange F, et al. Single and multiple dose pharmacokinetics of acetaminophen (paracetamol) in polymedicated very old patients with rheumatic pain. J Rheumatol 2001;28:182-184. Sandler DP, Smith JC, Weinberg CR, et al. Analgesic use and chronic renal disease. N Engl J Med 1989;320:1238-1243. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs. N Engl J Med 1994;331:1675-1679.

Henrich WL, Agodaoa LE, Barrett B, et al. Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the national Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis 1996;27:162-165. National Kidney Foundation. Analgesics. Available at: general/atoz/content/analgesics.html. Accessed February 2, 2003. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA 1994;273:1845-1850.

42. Schiodt FV, Röchling FA, Casey DL, et al. Acetaminophen toxicity in an urban county hospital. N Engl J Med 1997;337:1112-1117.

43. Cham E, Hall L, Ernst AA, et al. Awareness and use of over-the-counter pain medications: a survey of emergency department patients. South Med J 2002;95:529-535.

44. OTC acetaminophen labeling should warn about liver damage risk from higher-than-recommended doses{\}NDAC members. Health News Daily September 20, 2002;14. Available at: FDCViewerIncludes/frameset.asp?targetGUID={AACA1D0F-A5EE-48E9-9FAF-000E4D313FA2}&PopupWidth=730&PopupHeight=680. Accessed February 2, 2003.

45. Hyiek M, Heiman H, Skates SJ, et al. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA 1998;279:657-662.

46. Ebgert A. Postoperative pain management in the frail and elderly. Clin Geriatr Med 1996;12(part 3):583.

47. Bell GM, Schnitzer TJ. COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in the treatment of pain in the elderly. Clin Geriatr Med 2001;17:489-502.

48. Roberts LJ II, Morrow JD. Analgesic-antipyretic and anti-inflammatory agents and drugs employed in the treatment of gout. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's the Pharmacologic Basis of Therapeutics. 10th ed. New York, NY: McGraw-Hill; 2001:687-692.

49. APhA Special Report. Emerging therapies for inflammation and pain: the role of cyclooxygenase selectivity. 1999:1-19.

50. APhA Special Report. Therapeutic advances in the management of pain: the role of cyclooxygenase-2-specific inhibitors. 2002:1-21.

51. Carr DB, Jacox AK, Chapman CR, et al. Acute Pain Management: Operative or Medical Procedures and Trauma. Clinical Practice Guideline no. 1. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, US Department of Health and Human Services; February 1992. AHCPR publication 92-0032.

52. Varrassi G, Panella L, Piroli A et al. The effects of perioperative ketorolac infusion on postoperative pain and endocrine-metabolic response. Anesth Analg 1994;78:514-519.

53. Dahl V, Raeder JC. Nonopioid postoperative analgesia. Acta Anaesthesiol Scand 2000;44:1191-1203.

54. Morrison BW, Fricke J, Brown J, et al. The optimal analgesic dose of rofecoxib: overview of six randomized controlled trials. JAMA 2000;131:1729-1737.

55. Morrison BW, Christensen S, Yuan W, et al. Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial. Clin Ther 1999;21:943-953.

56. Myers SL, Brandt KD, Ehlich JW, et al. Synovial inflammation in patients with early osteoarthritis of the knee. J Rheumatol 1990;17:1662-1669.

57. Brandt KD. Toward pharmacologic modification of joint damage in osteoarthritis [editorial]. Ann Int Med 1995;122:874-875.

58. Ryu J, Treadwell BV, Mankin HJ. Biochemical and metabolic abnormalities in normal and osteoarthritis human articular cartilage. Arthritis Rheum 1984;27:49-57.

59. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998;105(Suppl 1B):31S.

60. Wolfe M, Lichtenstein D, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;34:1888-1899.

61. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin North Am 1996;6(part 3):489.

62. Agrawal NM, Roth S, Graham DY et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med 1991;115:195-200.

63. Robinson MG, Griffin JW Jr, Bowers J, et al. Effect of ranitidine on gas-troduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci 1989;34:424-428.

64. Ehsanullah RSB, Page MC, Tildesley G, et al. Prevention of gastrointestinal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine. BMJ 1988;297:1017-1021.

65. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998;338:719-726.

66. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-249.

67. Raskin JB, White RH, Jackson JE et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995;123:344-350.

68. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1998;338:727-724.

69. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.

70. Bombardier D, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Eng J Med 2000;343:1520-1528.

71. Silverstein FE, Faich G, Goldsterin JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-1255.

72. Chan FKL, Hung LCT, Suen BY, et al. Celecoxib vs diclofenac and omperazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-2110.

73. Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993;44:643-653.

74. Morales E, Mucksavage JJ. Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature. Pharmacotherapy 2002;22:1317-1321.

75. Brater D. Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 1999;107(Suppl 6A):65S.

76. Johnson AG, Simons LA, Simons J, et al. Non-steroidal anti-inflammatory drugs and hypertension in the elderly: a community-based cross-sectional study. Br J Clin Pharmacol 1993;35:455-459.

77. Gurwitz JH, Avorn J, Bohn RL, et al. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994;272:781-786.

78. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994;121:289-300.

79. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993;153:477-484.

80. LeLorier J, Bombardier C, Burgess E, et al. Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease. Can J Cardiol 2002;18:1301-1308.

81. Cheng HF, Harris RC. Does cyclooxygenase-2 affect blood pressure? Curr Hypertens Rep 2003;5:87-92.

82. Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002;90:959-963.

83. Collins R, Peto R, MacMahon S, et al. Epidemiology. Blood pressure, stroke and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990;335:827-838.

84. Johnson AG. NSAIDs and blood pressure: clinical importance for older patients. Drugs Aging 1998;12:17-27.

85. Hennekens C. Update on aspirin in the treatment and prevention of cardio vascular disease. Am Heart J 1999;137:S9.

86. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003;361:573-574.

87. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345:1809-1817.

88. Radbruch L, Grond S, Lehmann KA. A risk-benefit assessment of tramadol in the management of pain. Drug Safety 1996;15:8-29.

89. Schnitzer TJ. Managing chronic pain with tramadol in elderly patients. Clin Geriatr [serial on-line] 1999;7. Available at: cg/v7n8.shtml. Accessed February 18, 2003.

90. Dalgin P, TPS-OA Study Group. Comparison of tramadol and ibuprofen for the chronic pain of osteoarthritis [abstract]. Arthritis Rheum 1997;40(9 Suppl):S86.

91. Schnitzer T, Kamin M, TPS-NP Study Group. Ultram{reg} (tramadol HCl) maintains relief of osteoarthritis (OA) pain when substituted for high dose naproxen [abstract]. Arthritis Rheum 1998;40(9 Suppl):S86.

92. Roth SH. Efficacy and safety of tramadol HCl in breakthrough musculoskeletal pain attributed to osteoarthritis. J Rheumatol 1998;25:1358-1363.

93. Fricke JR, Karim R, Jordan D, et al. A double-blind, single-dose comparison of the analgesic efficacy of tramadol/acetaminophen combination tablets, hydrocodone/acetaminophen combination tablets, and placebo after oral surgery. Clin Ther 2002;24:953-968.

94. Mullican WS, Lacy JR. Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial. Clin Ther 2001;23:1429-1445.

95. Cicero TJ, Adams EH, Geller A, et al. A postmarketing surveillance program to monitor Ultram (tramadol hydrochloride) abuse in the United States. Drug Alcohol Depend 1999;57:7-22.

96. Ruoff GE. Slowing the initial titrate rate of tramadol improves tolerabil-ity. Pharmacotherapy 1999;19:88-93.

97. Kahn LH, Alderfer RJ, Graham DJ. Seizures reported with tramadol. JAMA 1997;278:1661.

98. RxList. Tramadol. Available at: tramadol_ids.htm. Accessed February 18, 2003.

99. Gloth FM III. Pain management in older adults: prevention and treatment. J Am Geriatr Soc 2001;49:188-199.

100. Gloth FM III. The use of a bisphosphonate (etidronate) to improve metastatic bone pain in three hospice patients. Clin J Pain 1995;11:333-335.

101. Hortobagyi GN, Theriault RL, Lester P, et al. Pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996;335:1785-1791.

Was this article helpful?

0 0
Arthritis Relief and Prevention

Arthritis Relief and Prevention

This report may be oh so welcome especially if theres no doctor in the house Take Charge of Your Arthritis Now in less than 5-Minutes the time it takes to make an appointment with your healthcare provider Could you use some help understanding arthritis Maybe a little gentle, bedside manner in your battle for joint pain relief would be great Well, even if you are not sure if arthritis is the issue with you or your friend or loved one.

Get My Free Ebook

Post a comment